144 related articles for article (PubMed ID: 36775200)
21. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
22. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
[TBL] [Abstract][Full Text] [Related]
23. Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients.
Ye P; Wu M; Cao J; Pei R; Yuan J; Zhuang H; Fang Y; Lu Y
Ann Hematol; 2024 May; ():. PubMed ID: 38809457
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
25. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies.
Nakamae H; Okamura H; Hirose A; Koh H; Nakashima Y; Nakamae M; Nishimoto M; Makuuchi Y; Kuno M; Harada N; Takakuwa T; Hino M
Cell Transplant; 2022; 31():9636897221112098. PubMed ID: 35906755
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies.
Lin X; Lu ZG; Song CY; Huang YX; Guo KY; Deng L; Tu SF; He YZ; Xu JH; Long H; Wu BY
Bone Marrow Transplant; 2015 Aug; 50(8):1092-7. PubMed ID: 25961770
[TBL] [Abstract][Full Text] [Related]
28. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study.
Yang J; Jiang J; Cai Y; Li S; Wan L; Zhu J; Liu H; Shao S; Bai H; Wang C; Song X
Bone Marrow Transplant; 2019 Jul; 54(7):1049-1057. PubMed ID: 30446741
[TBL] [Abstract][Full Text] [Related]
29. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
[TBL] [Abstract][Full Text] [Related]
30. Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan.
Ikegame K; Yoshida T; Yoshihara S; Daimon T; Shimizu H; Maeda Y; Ueda Y; Kaida K; Ishii S; Taniguchi K; Okada M; Tamaki H; Okumura H; Kaya H; Kurokawa T; Kodera Y; Taniguchi S; Kanda Y; Ogawa H
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1495-505. PubMed ID: 25921715
[TBL] [Abstract][Full Text] [Related]
31. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft
Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X
Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646
[TBL] [Abstract][Full Text] [Related]
32. Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation.
Wu L; Zhou M; Li Y; Chen X; Mo W; Wang C; Xu S; Zhou W; Deng T; Zhou R; Pan S; Wang S; Zhang Y
Transplant Cell Ther; 2023 Jul; 29(7):463.e1-463.e7. PubMed ID: 37098408
[TBL] [Abstract][Full Text] [Related]
33. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
34. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
35. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
36. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
37. Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases.
Zeng C; Chen Y; Hua J; Liu Y; Cheng TT; Ma X; Chen X; Wang SY; Xu YJ
Front Immunol; 2022; 13():980464. PubMed ID: 36119075
[TBL] [Abstract][Full Text] [Related]
38. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
[TBL] [Abstract][Full Text] [Related]
39. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia.
Huang Z; Yan H; Teng Y; Shi W; Xia L
Front Immunol; 2022; 13():1017850. PubMed ID: 36458000
[TBL] [Abstract][Full Text] [Related]
40. Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation.
Wu Y; Ni L; Liu Y; Yang L; Zhu P; Shi J; Wu Z; Zhao Y; Yu J; Lai X; Liu L; Fu H; Xie J; Huang H; Luo Y
Transplant Cell Ther; 2022 Jun; 28(6):331.e1-331.e10. PubMed ID: 35231641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
